<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01253473</url>
  </required_header>
  <id_info>
    <org_study_id>SYMB0012</org_study_id>
    <nct_id>NCT01253473</nct_id>
  </id_info>
  <brief_title>Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <acronym>SACOPD</acronym>
  <official_title>COPDGene Ancillary Proposal: Symbicort Intervention in &quot;Airway Predominant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Jewish Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to see if using anti-inflammatory to patients with airway
      disease chronic obstructive pulmonary disease (COPD) phenotype will be more effective than
      using these treatments in patients with loss of lung tissue. Symbicort plus
      ipratropium/albuterol will be used for 12 weeks in an open-label study in subjects with
      airway predominant COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects from the COPDGene study who have airway-predominant COPD on chest CT scan will be
      enrolled; a total of 40 subjects is planned.

      Subjects will all have background ipratropium-albuterol administered four times daily.
      Subjects will be randomized to receive budesonide (180 ug twice daily) or
      formoterol-budesonide (160/4.5 ug twice daily) for 12 weeks.

      The main objective is to explore novel outcomes: blood biomarkers and chest CT scan. Outcomes
      include lung function, walk distance, respiratory disease-specific health status, and
      expiratory chest CT scan gas trapping as an exploratory outcome.

      The primary outcome measure will be FEV1 pre-bronchodilator 12 hours after the last dose of
      study medication at the end of 12 weeks of treatment. FEV1 will be measured in the morning 6
      hours after the last dose of ipratropium/albuterol and 12 hours after the last dose of
      budesonide and budesonide/formoterol
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced expiratory volume in 1 second (FEV1) pre-bronchodilator</measure>
    <time_frame>12 weeks</time_frame>
    <description>FEV1 will be measured in the morning 6 hours after the last dose of ipratropium/albuterol and 12 hours after the last dose budesonide and budesonide/formoterol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Status</measure>
    <time_frame>12 weeks</time_frame>
    <description>Administer St. George's Respiratory Questionnaire at randomization and 12 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluated by the Modified Medical Research Council Dyspnea Scale at randomization and week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six minute walk distance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate six minute walk distance at randomization and 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity (FVC) pre-bronchodilator</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator FEV1</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported exacerbations</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator FVC</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CT scan gas trapping</measure>
    <time_frame>Before and 12 weeks after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>ipratropium/albuterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 puff 4 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>budesonide 180 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>budesonide/formoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>budesonide/formoterol 160/4.5 ug 2 puffs 4 times daily + ipratropium/albuterol 1 puffs four times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>Inhaled budesonide twice daily plus inhaled ipratropium/albuterol combination four times daily and every 4 hours as needed</description>
    <arm_group_label>Budesonide</arm_group_label>
    <other_name>Pulmicort Flexhaler®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide/formoterol</intervention_name>
    <description>Inhaled budesonide/formoterol (160/4.5 mcg Symbicort®) 2 puffs twice daily plus inhaled ipratropium/albuterol (Combivent®) 1 puff four times daily</description>
    <arm_group_label>budesonide/formoterol</arm_group_label>
    <other_name>Symbicort®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium/albuterol</intervention_name>
    <description>Inhaled ipratropium/albuterol combination 2 puffs four times daily</description>
    <arm_group_label>ipratropium/albuterol</arm_group_label>
    <arm_group_label>Budesonide</arm_group_label>
    <arm_group_label>budesonide/formoterol</arm_group_label>
    <other_name>Combivent®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. COPD GOLD Stage 2 and 3 (post-bronchodilator FEV1 35-80% predicted and FEV1/FVC &lt;0.7
             at the time of enrollment in COPDGene) by spirometry.

          2. Less than 15% of the lung &lt;-950 Hounsfield Units on COPDGene high-resolution
             inspiratoryChest CT scan (i.e. no evidence of significant emphysema)

          3. Greater than 10% gas trapping on COPDGene expiratory CT scan (i.e. evidence of small
             airway disease).

          4. No history of recent use (within the pat 8 weeks) of an inhaled or systemic
             corticosteroid.

          5. Body weight &lt;100 kg (low dose CT scans in subject with increased boyd weight can not
             be reliably analyzed).

        Exclusion Criteria:

          1. Exacerbation of COPD or other respiratory illness requiring antibiotics within the
             past 8 weeks.

          2. Previous adverse reaction to inhaled steroids, long-acting beta agonists, or
             long-acting anticholinergic medications.

          3. Symptomatic, untreated benign prostate hypertrophy.

          4. Allergy to peanuts.

          5. Glaucoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D Crapo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edwin K Silverman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barry J Make, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama Birmingham Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reliant Medical Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2010</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Jewish Health</investigator_affiliation>
    <investigator_full_name>Jennifer Brandorff</investigator_full_name>
    <investigator_title>Manager, Clinical Research Services, Regulatory</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

